PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that three presentations of late breaking trial results featuring Angiomax® (bivalirudin) and Cleviprex™ (clevidipine) have been scheduled for the American College of Cardiology (ACC) Annual Scientific Session March 24-27, 2007 in New Orleans.
